

September 6, 2004  
Contact:  
Birgit Grund  
Fresenius AG  
Investor Relations  
Tel. ++49 - 6172 - 608 2485  
Fax ++49 - 6172 - 608 2488  
e-mail: [ir-fre@fresenius.de](mailto:ir-fre@fresenius.de)  
Internet: <http://www.fresenius-ag.com>

## Fresenius Investor News

### **Fresenius Kabi is expanding its market presence in Australia**

Fresenius Kabi and the Australian pharmaceutical company Pharmatel Pty Ltd. have formed a joint venture to market infusion and nutrition therapy products in Australia. Fresenius Kabi holds a 25.1 % and Pharmatel a 74.9 % stake in the joint venture. Fresenius Kabi will increase its stake to 50.1 % until 2006. The new company, Pharmatel Fresenius Kabi Pty Ltd., was launched September 1, 2004 and sells products of Fresenius Kabi and of Pharmatel.

Pharmatel Pty Ltd., headquartered in Sydney, has a leading market position in Australia in the field of oncology compounding. It also specializes in gastrointestinal therapies including bowel lavage products for bowel cleansing prior to colonoscopy or surgery. The company had sales of approx. € 18 million in 2003 and employs 65 people. The current management team of Pharmatel will continue to hold executive positions within the joint venture.

“The joint venture with Pharmatel is a further step of our strategy to expand into growth markets. Its compounding facilities in Sydney and Melbourne are a perfect platform for Fresenius Kabi to enter the parenteral nutrition compounding market in Australia. Pharmatel has excellent relationships with hospitals, high local awareness and a very good reputation for customer service. It is our goal to become one of the leading hospital suppliers in Australia”, Mats Henriksson, Member of the Management Board of Fresenius Kabi and responsible for the Region Asia Pacific, commented.

“By partnering with Fresenius Kabi, Pharmatel strengthens its middle and long term position in the Australian market”, Pharmatel Chairman and Managing Director George Shortis said.

Fresenius Kabi is the leading European provider of nutrition and infusion therapy for critically and chronically ill patients in the hospital and outpatient environment and has strong market positions in Asia Pacific and Latin America. Fresenius Kabi had sales of € 1,463 million in 2003 and employs around 11,400 employees in more than 30 countries. Fresenius Kabi is a company of the Fresenius healthcare group.

For more information please visit Fresenius Kabi's website at [www.fresenius-kabi.com](http://www.fresenius-kabi.com)

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.